Potassium Carbonate → 7-(1,2-dimethyl-1H-imidazol-5-yl)-N-(3-ethyl-1-((6-methylpyridin-2-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide

HRID 79360

反応式

HRID 79360 の反応式
Br[C:2]1[CH:7]=[CH:6][N:5]2[C:8]([C:11]([NH:13][C:14]3[CH:22]=[CH:21][CH:20]=[C:19]4[C:15]=3[C:16]([CH2:31][CH3:32])=[N:17][N:18]4[CH2:23][C:24]3[CH:29]=[CH:28][CH:27]=[C:26]([CH3:30])[N:25]=3)=[O:12])=[CH:9][N:10]=[C:4]2[CH:3]=1.O1C=CC=C1P(C1OC=CC=1)C1OC=CC=1.[CH3:49][N:50]1[CH:54]=[CH:53][N:52]=[C:51]1[CH3:55].C([O-])([O-])=O.[K+].[K+]>CN(C=O)C.C([O-])(=O)C.C([O-])(=O)C.[Pd+2]>[CH3:49][N:50]1[C:54]([C:2]2[CH:7]=[CH:6][N:5]3[C:8]([C:11]([NH:13][C:14]4[CH:22]=[CH:21][CH:20]=[C:19]5[C:15]=4[C:16]([CH2:31][CH3:32])=[N:17][N:18]5[CH2:23][C:24]4[CH:29]=[CH:28][CH:27]=[C:26]([CH3:30])[N:25]=4)=[O:12])=[CH:9][N:10]=[C:4]3[CH:3]=2)=[CH:53][N:52]=[C:51]1[CH3:55]

参加物

7

反応物 4

HCID 11430Potassium CarbonateHCID 156171,2-DimethylimidazoleHCID 521585Tris(furan-2-yl)phosphaneHCID 672595577-Bromo-N-(3-ethyl-1-((6-methylpyridin-2-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide

生成物 1

HCID 672601647-(1,2-dimethyl-1H-imidazol-5-yl)-N-(3-ethyl-1-((6-methylpyridin-2-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide収率 15%

試薬・触媒・溶媒 2

HCID 167845palladium(II) acetate触媒HCID 6228Dimethylformamide溶媒

反応条件

温度
140 °C

実験手順

To 7-bromo-N-(3-ethyl-1-((6-methylpyridin-2-yl)methyl)-1H-indazol-4-yl) imidazo[1,2-a]pyridine-3-carboxamide (prepared as in Example 127, Step A; 129 mg, 0.264 mmol) in DMF (4 mL) was added trifuran-2-ylphosphine (12.2 mg, 0.0527 mmol), 1,2-dimethyl-1H-imidazole (50.7 mg, 0.527 mmol), palladium diacetate (5.92 mg, 0.0264 mmol) and K2CO3 (72.9 mg, 0.527 mmol). The reaction mixture was purged with argon, sealed and heated to 140° C. for 3 hours. The mixture was cooled to ambient temperature, diluted with DCM (20 mL) and washed with H2O. The organic phase was dried (Na2SO4) and concentrated under reduced pressure. The residue was purified by silica gel chromatography (DCM/MeOH/NH4OH, 10:1:0.1) to provide the final product (20 mg). MS (ES+APCI) m/z=505 (M+H).

後処理

  1. customThe reaction mixture was purged with argon
  2. customsealed
  3. temperatureThe mixture was cooled to ambient temperature
  4. additiondiluted with DCM (20 mL)
  5. washwashed with H2O
  6. dry with materialThe organic phase was dried (Na2SO4)
  7. concentrationconcentrated under reduced pressure
  8. customThe residue was purified by silica gel chromatography (DCM/MeOH/NH4OH, 10:1:0.1)

出典と根拠

ORDレコード
ord-cdaf755798a4457789dfc84e337d2c2f
出典データセット
uspto-grants-2014_09
特許番号
US08841455B2

関連ノート

読み込み中…